VEGF-A早期升高与呼吸机相关性肺炎消退相关:临床与实验证据
该研究在82例呼吸机相关性肺炎(VAP)患者中连续7天检测血清VEGF-A,并在小鼠铜绿假单胞菌肺炎模型中验证。第5天VEGF-A较基线升高超过45%的患者VAP消退率更高(65.2% vs 36.1%,P=0.014),消退更早(log-rank P=0.005),且不依赖病原体。小鼠肺内VEGF-A在124小时显著升高,贝伐珠单抗预处理后VEGF-A下降而TNF-α和MPO升高。
要点
- VAP患者第5天VEGF-A升高>45%与更高的消退率和更早消退相关。
- VEGF-A升高与VAP消退的关联不依赖于病原体类型。
- 小鼠模型中VEGF-A升高可能参与肺炎炎症消退过程。
核心结论
- VAP患者循环VEGF-A升高与VAP消退相关。
- 小鼠研究提示VEGF-A升高可能与肺部炎症消退相关。
研究设计与样本
- 临床部分连续7天用免疫吸附法检测82例VAP患者血清VEGF-A,并与VAP消退进行相关性分析。
- 实验部分以铜绿假单胞菌气管内攻击小鼠,在攻击后24、48和124小时获取支气管肺泡灌洗液和肺组织。
主要发现
- 第5天VEGF-A较基线升高不足45%的患者VAP消退率为36.1%,升高超过45%的患者消退率为65.2%(P=0.014)。
- VEGF-A升高超过45%的患者VAP消退更早(log-rank:7.99;P=0.005),且该关联不依赖于病原体。
- 在小鼠支气管肺泡灌洗液和肺组织中,VEGF-A在124小时显著升高,而其他介质未见此变化。
- 贝伐珠单抗预处理的小鼠VEGF-A浓度降低,而TNF-α和MPO显著升高。
关键数值与推荐
- VAP消退率:VEGF-A升高<45%组为36.1%,升高>45%组为65.2%(P=0.014)。
- VAP消退时间:log-rank统计量7.99,P=0.005。
临床怎么用
- 动态监测VAP患者血清VEGF-A水平可能有助于判断肺炎消退趋势。
- VEGF-A升高与VAP消退的关联提示其或可作为炎症消退的生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The role of vascular endothelial growth factor (VEGF)-A in the resolution of ventilator-associated pneumonia (VAP) was investigated in clinical and mouse pneumonia models. METHODS: VEGF-A was measured for seven consecutive days by an immunosorbent assay in sera of 82 patients with VAP and changes from baseline were correlated with the resolution of VAP. Experimental animals were challenged intratracheally with Pseudomonas aeruginosa. Mouse bronchoalveolar lavage (BAL) samples and segments of lung tissue were obtained at 24, 48 and 124 h after bacterial challenge. Levels of VEGF-A, tumour Necrosis Factor alpha (TNF-α), interleukin (IL)-1β, interferon-gamma (IFNγ) and myeloperoxidase (MPO) activity were measured in these samples. RESULTS: VAP resolved in 36.1% of patients with a less than 45% increase of VEGF-A on day 5 compared to 65.2% of patients with a more than 45% increase (P = 0.014). This was also accompanied by an earlier resolution of VAP (log-rank: 7.99; P = 0.005) and it was not pathogen-specific. The increase of VEGF-A was an independent variable associated with VAP resolution in forward logistic regression analysis where Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA) scores were included as independent variables. VEGF-A in mouse BAL and lung tissue increased significantly at 124 h but not with the other mediators. In mice pre-treated with bevacizumab, VEGF-A concentrations decreased while TNF-α and MPO significantly increased. CONCLUSION: In patients, an association between increased levels of circulating VEGF-A and VAP resolution was observed. The mouse study suggests that elevated VEGF-A levels may be associated with lung inflammation resolution. CLINICAL TRIAL REGISTRATION: NCT00297674 at www.clinicaltrials.gov.
引用
- Strouvalis I, Routsi C, Adamopoulou M, et al. Early increase of VEGF-A is associated with resolution of ventilator-associated pneumonia: Clinical and experimental evidence. Respirology. 2018. PMID: 29741298. doi:10.1111/resp.13320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。